Faruqi & Faruqi, LLP Investigates Potential Claims Against Applied Therapeutics, Inc. for Violating Securities Laws

Summary

Faruqi & Faruqi, LLP is investigating potential claims against Applied Therapeutics, Inc. for alleged violations of federal securities laws. Investors who suffered losses from January 3, 2024, to December 2, 2024, are encouraged to contact the firm. The investigation follows the FDA’s complete response letter regarding the company’s new drug application for govorestat, which led to a significant drop in its stock price. A class action has been filed, with a lead plaintiff application deadline of February 18, 2025.

Impact Analysis

This event is classified as a company-level event as it directly pertains to Applied Therapeutics, Inc. and its legal and financial standing. The primary impact is on the company’s stock price, which has already seen a significant drop due to the FDA’s response to their drug application. The legal investigation could lead to further declines if investors anticipate potential fines, settlements, or reputational damage. The first-order effects include immediate investor actions like selling shares or avoiding new purchases, while second-order effects may involve increased scrutiny from regulators or a shift in investor trust. Investment opportunities may arise in shorting the stock or considering affected biotech ETFs, but risks involve potential legal resolutions that could stabilize or improve the company’s outlook if successfully managed.